- Home
- ABEO
as 07-26-2024 4:00pm EST
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CLEVELAND |
| Market Cap: | 186.0M | IPO Year: | 1980 |
| Target Price: | $19.00 | AVG Volume (30 days): | 383.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.83 - $9.01 | Next Earning Date: | 08-06-2024 |
| Revenue: | $3,500,000 | Revenue Growth: | 227.72% |
| Revenue Growth (this year): | -91.26% | Revenue Growth (next year): | 5414.38% |
Stock Insider Trading Activity of Abeona Therapeutics Inc. (ABEO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Alvino Mark | ABEO | Director | Jun 17 '24 | Sell | $4.51 | 25,890 | $116,763.90 | 36,926 | SEC Form 4 |
| Alland Leila | ABEO | Director | May 16 '24 | Buy | $4.71 | 11,000 | $51,799.00 | 82,857 | SEC Form 4 |
| Charles Faith L. | ABEO | Director | Apr 26 '24 | Buy | $3.28 | 7,550 | $24,764.00 | 78,323 | SEC Form 4 |
| O'Malley Brendan M. | ABEO | SVP, General Counsel | Apr 25 '24 | Buy | $3.24 | 8,600 | $27,864.00 | 188,718 | SEC Form 4 |
| Vazzano Joseph Walter | ABEO | Chief Financial Officer | Apr 25 '24 | Buy | $3.14 | 5,608 | $17,609.12 | 233,868 | SEC Form 4 |
| Seshadri Vishwas | ABEO | Chief Executive Officer | Apr 25 '24 | Buy | $3.20 | 10,000 | $32,000.00 | 538,260 | SEC Form 4 |
| Seshadri Vishwas | ABEO | Chief Executive Officer | Feb 6 '24 | Buy | $4.39 | 20,000 | $87,800.00 | 528,260 | SEC Form 4 |
| Alvino Mark | ABEO | Director | Jan 17 '24 | Sell | $5.11 | 7,084 | $36,199.24 | 62,816 | SEC Form 4 |
Latest Abeona Therapeutics Inc. News
ABEO Breaking Stock News: Dive into ABEO Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Institutional investors own a significant stake of 39% in Abeona Therapeutics Inc. (NASDAQ:ABEO)
MT Newswires
15 days ago
Abeona Therapeutics Partners with Beacon Therapeutics to Develop Ophthalmic Gene Therapies
GlobeNewswire
16 days ago
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
GlobeNewswire
19 days ago
Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
GuruFocus.com
a month ago
Insider Sale: Director Christine Silverstein Sells Shares of Abeona Therapeutics Inc (ABEO)
MT Newswires
a month ago
Abeona Therapeutics Files for $300 Million Mixed Shelf, $75 Million At-The-Market Offering
Business Wire
2 months ago
Net Asset Value(s)
AFP
2 months ago
Irish, Czechs hold EU vote after Dutch far-right gains
Compare ABEO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABEO Abeona Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.